Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
AEON - AEON Biopharma, Inc.
Market Cap 157.06M P/E - EPS this Y 442.90% Ern Qtrly Grth -
Income 42.48M Forward P/E - EPS next Y -195.80% 50D Avg Chg -
Sales - PEG - EPS past 5Y - 200D Avg Chg -
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -38.00%
Recommedations 2.00 Quick Ratio 0.33 Shares Outstanding 39.52M 52W Low Chg 30.00%
Insider Own 36.64% ROA -597.69% Shares Float 17.55M Beta 0.34
Inst Own 23.87% ROE - Shares Shorted/Prior 68.65K/131.52K Price 7.33
Gross Margin - Profit Margin - Avg. Volume 318,912 Target Price 5.00
Oper. Margin - Earnings Date - Volume 107,564 Change -6.03%
Healthcare | Biotechnology | United States
About AEON Biopharma, Inc.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

AEON Biopharma, Inc. News
11/13/24 AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
09/30/24 AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting
08/21/24 AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
08/19/24 AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
08/12/24 AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07/09/24 AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
05/29/24 Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround
05/29/24 AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan
05/14/24 AEON Biopharma Reports First Quarter 2024 Financial Results
05/09/24 AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
05/09/24 AEON Biopharma Provides Update on Development Pipeline
05/03/24 US Equity Markets Close Higher Friday Following Weak Jobs Report
05/03/24 AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
04/19/24 Here's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock Now
03/30/24 CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
03/29/24 AEON Biopharma Announces Redemption of Public Warrants
03/29/24 AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
03/19/24 AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
03/19/24 AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
01/18/24 AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference